Valence8 US LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 12, 2025), Valence8 US LP reported 10 stock positions worth $208.2 million. Its top holding was iShares MSCI USA Quality Fac (QUAL) at 28.0% of the portfolio, followed by Invesco QQQ Trust Series 1 (QQQ, 20.6%) and iShares MSCI International Q (IQLT, 17.7%). Compared with Q3 2024, it opened 1 new position, sold out of 31, added to 4 and reduced 5. The biggest buy was a new position in iShares Expanded Tech-Softwa (IGV) and the biggest sale iShares MSCI United Kingdom (EWU, shares −44%).
- Most Recent 13F
- Q2 2026
- Location
- Cambridge, MA
- CIK
- 0001943819
- Portfolio Value
- $208.2M (Q4 2024)
- SEC Filing
- 0001172661-25-000713 ↗ filed Feb 12, 2025
Holdings Value
Holdings 10 stocks · $208.2M
| QUAL iShares MSCI USA Quality Fac | 27.96% | 326,910 | $58.2M | Reduce -3.1% |
| QQQ Invesco QQQ Trust Series 1 | 20.57% | 83,798 | $42.8M | Reduce -4.9% |
| IQLT iShares MSCI International Q | 17.66% | 990,439 | $36.8M | Reduce -3.5% |
| EFV iShares MSCI Eafe Value ETF | 10.19% | 404,248 | $21.2M | Add +1.3% |
| VTV Vanguard Mrngstr Val ETF-Aui | 7.92% | 97,398 | $16.5M | Add +0.8% |
| XLP SS Consumer Staples Sel Sect | 6.27% | 166,161 | $13.1M | Add +0.5% |
| IGV iShares Expanded Tech-Softwa | 3.75% | 77,909 | $7.8M | New |
| EWU iShares MSCI United Kingdom | 1.90% | 116,688 | $4.0M | Reduce -44.3% |
| XLU St Sr Utl SL SE SPDR ETF-Usd | 1.90% | 52,247 | $4.0M | Add +0.6% |
| EWJ iShares MSCI Japan ETF | 1.89% | 58,649 | $3.9M | Reduce -46.0% |
Portfolio Sells Q3 2024 → Q4 2024
| EWU iShares MSCI United Kingdom | Reduce -44.3% | 1.90% | −1.51 |
| EWJ iShares MSCI Japan ETF | Reduce -46.0% | 1.89% | −1.50 |
| IQLT iShares MSCI International Q | Reduce -3.5% | 17.66% | −0.90 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −0.44 |
| BMY Bristol-Myers Squibb Co. | Sold out | 0.00% | −0.40 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −0.30 |
| INSM Insmed Inc. | Sold out | 0.00% | −0.25 |
| INDV Indivior Ltd. | Sold out | 0.00% | −0.25 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −0.24 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.23 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.21 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −0.20 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −0.18 |
| JANX Janux Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −0.15 |
| TYRA Tyra Biosciences Inc. | Sold out | 0.00% | −0.14 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.13 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −0.12 |
| NTLA Intellia Therapeutics Inc. | Sold out | 0.00% | −0.12 |
| VIR Vir Biotechnology Inc. | Sold out | 0.00% | −0.11 |
| BPMC Blueprint Medicines Corp. | Sold out | 0.00% | −0.11 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.10 |
| ENTA Enanta Pharmaceuticals Inc. | Sold out | 0.00% | −0.09 |
| RLAY Relay Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| ZVRA Zevra Therapeutics Inc. | Sold out | 0.00% | −0.07 |
| ERAS Erasca Inc. | Sold out | 0.00% | −0.06 |
| SLDB Solid Biosciences Inc. | Sold out | 0.00% | −0.05 |
| VTGN Vistagen Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| ZURA Zura Bio Ltd. | Sold out | 0.00% | −0.03 |
| ALEC Alector Inc. | Sold out | 0.00% | −0.03 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.03 |
| CYPH Cypherpunk Technologies Inc. | Sold out | 0.00% | −0.02 |
| NKTR Nektar Therapeutics | Sold out | 0.00% | −0.01 |
| KEZAR LIFE SCIENCES INC | Sold out | 0.00% | −0.01 |
| QUAL iShares MSCI USA Quality Fac | Reduce -3.1% | 27.96% | +1.58 |
| QQQ Invesco QQQ Trust Series 1 | Reduce -4.9% | 20.57% | +1.82 |
Portfolio Buys Q3 2024 → Q4 2024
Options Activity Q3 2024 → Q4 2024
| AZN Astrazeneca PLC-Spons ADR | call | Sold out | 64,000 | $5.0Mbefore exit |
| AMGN Amgen Inc. | put | Sold out | 2,000 | $644Kbefore exit |
| AMGN Amgen Inc. | call | Sold out | 2,000 | $644Kbefore exit |
| SLNO Soleno Therapeutics Inc. | call | Sold out | 12,500 | $631Kbefore exit |
| CRSP Crispr Therapeutics AG | call | Sold out | 13,100 | $615Kbefore exit |
| INSM Insmed Inc. | call | Sold out | 6,600 | $482Kbefore exit |
| NVO Novo-Nordisk A/S-Spons ADR | call | Sold out | 3,900 | $464Kbefore exit |
| FLNA Filana Therapeutics Inc. | put | Sold out | 14,100 | $415Kbefore exit |
| RARE Ultragenyx Pharmaceutical Inc. | call | Sold out | 6,900 | $383Kbefore exit |
| APLS Apellis Pharmaceuticals Inc. | call | Sold out | 13,100 | $378Kbefore exit |
| AVDL Avadel Pharmaceuticals Ltd. | call | Sold out | 26,200 | $344Kbefore exit |
| VRDN Viridian Therapeutics Inc. | call | Sold out | 13,100 | $298Kbefore exit |
| MRNA Moderna Inc. | call | Sold out | 4,100 | $274Kbefore exit |
| CLDX Celldex Therapeutics Inc. | put | Sold out | 6,500 | $221Kbefore exit |
| APLT Applied Therapeutics Inc. | call | Sold out | 20,300 | $173Kbefore exit |
| ALT Altimmune Inc. | call | Sold out | 26,200 | $161Kbefore exit |
| ALT Altimmune Inc. | put | Sold out | 23,500 | $144Kbefore exit |
| IOVA Iovance Biotherapeutics Inc. | call | Sold out | 13,100 | $123Kbefore exit |
| JANX Janux Therapeutics Inc. | put | Sold out | 2,300 | $104Kbefore exit |
| BCRX Biocryst Pharmaceuticals Inc. | call | Sold out | 13,100 | $100Kbefore exit |
| CCCC C4 Therapeutics Inc. | call | Sold out | 10,500 | $60Kbefore exit |
| GOSS Gossamer Bio Inc. | call | Sold out | 20,700 | $20Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $300.5M | QUAL, QQQ, BIL, IQLT, XLP |
| Q1 2026 | 14 | $286.1M | QUAL, BIL, IQLT, QQQ, EFV |
| Q4 2025 | 15 | $337.5M | BIL, QUAL, QQQ, IQLT, EFV |
| Q3 2025 | 14 | $291.7M | QUAL, QQQ, IQLT, BIL, EFV |
| Q2 2025 | 12 | $237.6M | QUAL, QQQ, IQLT, EFV, VTV |
| Q1 2025 | 10 | $213.3M | QUAL, IQLT, QQQ, EFV, VTV |
| Q4 2024 | 10 | $208.2M | QUAL, QQQ, IQLT, EFV, VTV |
| Q3 2024 | 40 | $229.4M | QUAL, QQQ, IQLT, EFV, VTV |
| Q2 2024 | 9 | $191.9M | QUAL, QQQ, IQLT, EFV, VTV |
| Q1 2024 | 9 | $191.8M | QUAL, IQLT, QQQ, EFV, VTV |